Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

Investors Business Daily

Dow Jones Futures Rise: Nvidia Leads New Buys; Tesla Runs Past Resistance On Elon Musk Move

Dow Jones Futures Rise: Nvidia Leads New Buys; Tesla Runs Past Resistance On Elon Musk Move

Nvidia and several other leaders flashed buy signals as the market roared. Investors should take advantage, but it's a jungle out there.

Investors Business Daily

Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound

Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound

Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Doctors warn unplanned 'Ozempic babies' may be harmed by weight-loss drugs

Women using weight-loss drug semaglutide have reported surprise pregnancies, but doctors warn the risk to babies is not yet clear

Evening Standard

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Persistent shortage of growth hormone frustrates parents and clinicians

As a shortage of growth hormone used to treat rare diseases in children drags on, families and doctors are struggling with insurers' requirements to get prescriptions filled.

Albo is right to want to make things in Australia. He’ll just need a bit more cash

It’s a new era of geopolitical competition out there, where old certainties of ‘free trade’ are ending. Australia needs to pivot — will Albanese’s policy be enough?

inkl

Read news from The Economist, FT, and more,
with one subscription

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investors Business Daily

Shark Tank's Mark Cuban speaks out on weight-loss drugs

Shark Tank's Mark Cuban speaks out on weight-loss drugs

A conversation TheStreet engaged in with Cuban about weight-loss drugs shifted from Novo Nordisk's Ozempic to something new from Eli Lilly.

3 Best Mega-Cap Stocks for Dividend Investors

3 Best Mega-Cap Stocks for Dividend Investors

Discover the compelling stories behind three mega-cap dividend stocks that have caught the attention of analysts and investors alike.

Ozempic success story: 'Weight-loss drugs, costs and my health'

Ozempic success story: 'Weight-loss drugs, costs and my health'

Ozempic is pricey, but a great health insurance plan paved the way for a software professional to experience dramatic results.

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

Investors Business Daily

Costco enters a controversial industry with its latest move

Costco enters a controversial industry with its latest move

The retail giant is expanding one of its beloved programs to include a growing trend.

Get all your
news in one place.

100’s of premium titles.
One news app.

Ozempic, weight-loss drugs force a change of focus on health

The effectiveness of weight-loss drugs mean people who take them have more fitness challenges to confront.

Ozempic, weight-loss drugs rise and the fitness industry reacts

The increasing popularity of GLP-1 medications such as Ozempic triggers some changes.

The Guardian - UK

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

Investors Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Get all your
news in one place.

100’s of premium titles.
One news app.

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Investors Business Daily

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly — Beats Expectations In Just 28 Days

Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug beat expectations in a 28-day study.

Investors Business Daily

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

Mark Cuban shares thoughts on Ozempic and his drug company

The Shark Tank billionaire has a question for Novo Nordisk and TheStreet seeks an answer.

Investors Business Daily

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

International Business Times

Nvidia, Novo Nordisk Forge Path To Medical Breakthroughs With AI Supercomputer Gefion

Nvidia and Novo Nordisk's joint venture, Gefion, represents a groundbreaking endeavor in medical research, leveraging AI technology.

Novo Nordisk Foundation Expanding Grants Internationally

Novo Nordisk Foundation expands global grant allocation to drive research and innovation beyond Denmark, fostering collaborations and excellence worldwide.

1 … 5 6 7 8

People

Anthony Albanese

Kritika SarmahHer

Todd Rosenbluth

Jennifer Miller

Margaret Kaczor Andrew

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

235,675 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play